Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.86 USD | +7.14% | -2.39% | -3.18% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 16.49M | Capitalization | 500M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -111M | EV / Sales 2024 * | - |
Net cash position 2024 * | 260M | Net cash position 2025 * | 139M | EV / Sales 2025 * | 21.9 x |
P/E ratio 2024 * |
-3.9
x | P/E ratio 2025 * |
-4.85
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | +7.14% | ||
1 week | -2.39% | ||
Current month | -13.11% | ||
1 month | -11.43% | ||
3 months | -1.82% | ||
6 months | +22.77% | ||
Current year | -3.18% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 04-03-25 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 19-01-31 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Albert Cha
BRD | Director/Board Member | 51 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 8 M€ | +9.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 11.86 | +7.14% | 2,152,861 |
24-03-27 | 11.07 | -0.36% | 266,046 |
24-03-26 | 11.11 | -0.18% | 520,289 |
24-03-25 | 11.13 | -6.08% | 514,138 |
24-03-22 | 11.85 | -2.47% | 270,724 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.18% | 500M | |
+0.44% | 90.78B | |
+9.61% | 43.96B | |
-16.67% | 31.34B | |
+44.99% | 23.45B | |
-9.42% | 16.48B | |
-25.92% | 15.03B | |
-9.27% | 12.79B | |
-7.57% | 12.19B | |
+0.07% | 8.5B |